SANGAMO THERAPEUTICS, INC 8K

Sangamo Therapeutics, Inc. filed its July 2026 Chapter 11 Monthly Operating Report, highlighting $18 million in replacement DIP financing, repayment of its initial DIP facility, and continued operating losses under bankruptcy protection.

Sangamo Therapeutics, Inc., which commenced a Chapter 11 bankruptcy case in the District of Delaware on June 23, 2026, filed a Monthly Operating Report for the period July 1–31, 2026 detailing its operations as a debtor-in-possession, including $18 million of new replacement debtor-in-possession (DIP) financing from Future Solution Investments LLC (used in part to repay $10.5 million outstanding under an initial DIP facility), cash receipts and disbursements, a monthly net loss of approximately $11.2 million, postpetition borrowing and authorized payments on prepetition obligations pursuant to first-day and DIP orders, and related attestations by Interim Chief Financial Officer Nikunj Jain on September 2, 2026.

Filing Facts

CIK

1001233

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-105905

Alert Tier

8